Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

Intravenous immunoglobulin (IVIg) is a potential alternative treatment for anti-neutrophil cytoplasm antibody (ANCA)-associated systemic vasculitis (AASV) with less toxicity than conventional immunosuppressive agents. This randomized, placebo-controlled trial aimed to investigate the efficacy of a s...

Full description

Bibliographic Details
Main Authors:	Jayne, DR, Chapel, H, Adu, D, Misbah, S, O'Donoghue, D, Scott, D, Lockwood, C
Format:	Journal article
Language:	English
Published:	2000

Similar Items

Placebo-controlled trial of intravenous immunoglobulin in ANCA-associated systemic vasculitis.
by: Jayne, D, et al.
Published: (1999)

Comparison of disease activity measures for ANCA-associated vasculitis.
by: Merkel, P, et al.
Published: (2004)

Cardiovascular outcomes in ANCA associated vasculitis
by: Mukhtyar, C, et al.
Published: (2008)

Diagnosis and management of ANCA associated vasculitis.
by: Berden, A, et al.
Published: (2012)

Explaining fatigue in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
by: Suppiah, R, et al.
Published: (2011)

Explaining fatigue in ANCA-associated vasculitis.
by: Basu, N, et al.
Published: (2013)

Predictors of renal involvement in ANCA associated vasculitis
by: Kronbichler, A, et al.
Published: (2018)

Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.
by: Arnold, D, et al.
Published: (2010)

Markers for work disability in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

Long-term survival of ANCA-associated vasculitis
by: Flossmann, O, et al.
Published: (2009)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
by: Merkel, P, et al.
Published: (2009)

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
by: Lapraik, C, et al.
Published: (2007)

Intravenous immunoglobulin therapy.
by: Chapel, H
Published: (1996)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
by: Salisbury, E, et al.
Published: (2003)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
by: Basu, N, et al.
Published: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis
by: Basu, N, et al.
Published: (2014)

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
by: Ntatsaki, E, et al.
Published: (2014)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
by: Jones, R, et al.
Published: (2010)

Damage assessment in ANCA-associated vasculitis.
by: Bhamra, K, et al.
Published: (2012)

Cutaneous manifestations of ANCA-associated vasculitis
by: Chiesafuxench, Z, et al.
Published: (2016)

Outcome measures in ANCA-associated vasculitis.
by: Suppiah, R, et al.
Published: (2010)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)
by: Salisbury, E, et al.
Published: (2004)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
by: Basu, N, et al.
Published: (2014)

Long-term patient survival in ANCA-associated vasculitis
by: Flossmann, O, et al.
Published: (2011)

Long-term patient survival in ANCA-associated vasculitis.
by: Flossmann, O, et al.
Published: (2011)

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
by: Yew, S, et al.
Published: (2012)

Long-term patient survival in ANCA-associated vasculitis.
by: Flossmann, O, et al.
Published: (2011)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
by: Suppiah, R, et al.
Published: (2011)

Home intravenous immunoglobulin therapy.
by: Chapel, H, et al.
Published: (1988)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
by: Basu, N, et al.
Published: (2012)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
by: Luqmani, R, et al.
Published: (2007)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
by: Suppiah, R, et al.
Published: (2011)

Plasma exchange and glucocorticoids in severe anca-associated vasculitis
by: Walsh, M, et al.
Published: (2020)

Maintenance of clinical remission in ANCA-associated vasculitis.
by: Luqmani, R
Published: (2013)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
by: Yew, S, et al.
Published: (2012)

EULAR/ERA-EDTA RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS
by: Yates, M, et al.
Published: (2016)

Cutaneous manifestations of ANCA-associated vasculitis are common, varied, and associated with systemic disease
by: Micheletti, R, et al.
Published: (2017)

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
by: Yates, M, et al.
Published: (2016)

Hepatitis C and intravenous immunoglobulin - Concluding remarks
by: Chapel, H
Published: (1996)